The Intersection of Law & Life Sciences

Transcript of remarks delivered by Judge Pauline Newman, November 10, 2026, at IPWatchdog Studios

Remarks delivered by Judge Pauline Newman, Circuit Judge, U.S. Court of Appeals for the Federal Circuit, on Tuesday, November 10, 2026, at the fifth annual Life Sciences Masters™ conference hosted by IPWatchdog, Inc.  The transcript below and time stamps were verified on November 15, 2026 (by Gene Quinn) against the IPWatchdog video uploaded to our YouTube Channel (see below). 

Editorial Summary by IPWatchdog: Uncertainty in patent rights undermines the investment needed to turn scientific breakthroughs into commercial products—but accepting that uncertainty is a choice. Judge Pauline Newman draws on her experience in industry and the policy discussions that helped shape the Federal Circuit to connect today’s life sciences challenges with the conditions that drove an earlier era of patent reform. She explains why predictable, reliable patent protection matters to research investment, commercialization, and the ability to recover the costs of failed research as well as successful discoveries. Her message to IP counsel, industry leaders, and policymakers is direct: addressing the weaknesses of the patent system requires looking beyond how to navigate existing law and engaging in the work of changing it.

Speaker Biography: Hon. Pauline Newman. Judge Newman was appointed by President Ronald Reagan in 1984 to the United States Court of Appeals for the Federal Circuit. From 1982 to 1984, Judge Newman was Special Adviser to the United States Delegation to the Diplomatic Conference on the Revision of the Paris Convention for the Protection of Industrial Property. She served on the advisory committee to the Domestic Policy Review of Industrial Innovation from 1978 to 1979 and on the State Department Advisory Committee on International Intellectual Property from 1974 to 1984. From 1969 to 1984, Judge Newman served as director, Patent, Trademark and Licensing Department, FMC Corp. From 1961 to 1962 she worked for the United Nations Educational, Scientific and Cultural Organization as a science policy specialist in the Department of Natural Sciences. She served as patent attorney and house counsel of FMC Corp. from 1954 to 1969 and as research scientist, American Cyanamid Co. from 1951 to 1954. Judge Newman received a B.A. from Vassar College in 1947, an M.A. from Columbia University in 1948, a Ph.D. from Yale University in 1952 and an LL.B. from New York University School of Law in 1958.

TRANSCRIPT

[Renee Quinn] (0:00 – 0:12)

Hello everyone, welcome to IP Watchdog Unleashed where each week we journey into the world of intellectual property to discuss the laws, news, policy, and politics of innovation, technology, and creativity.

[Gene Quinn] (0:13 – 1:02)

I always say when someone can be introduced with one sentence you know that they’ve reached the pinnacle of whatever industry they’re in and Judge Newman really probably needs not even that full sentence. Judge Newman carries with her so much gravitas that just the name alone is probably enough of an introduction. She’s been a hero to so many of us.

We’ve looked up to her for so long. I’m honored to call her a friend and a mentor and she’s obviously a member of the federal circuit. She’s been so for over 40 years, and she is here on our stage again.

Judge, we’re honored to have you. She will talk briefly about her view of the intersection of life sciences and intellectual property. Judge, please feel free to take it away.

[Judge Newman] (1:07 – 9:50)

Well, thank you Gene and hello to everyone. I’m delighted to be here with you and particularly at this particular moment in your program because as I was listening to the previous panel I was having the most extraordinary sense of deja vu and so I’m going to depart a little bit from the grand philosophical theory that I have been thinking about and wanting to spread and to give you what I suppose I could summarize as more of a pep talk because as I listened to the problems that we, you, are all confronting and that I have been aware of for the last few years, these statements could have been made word for word almost 50 years ago when the federal circuit was just a gleam in the eye of a few people who thought that such changes in judicial structure or let’s say improvements were impossible. This was the mid-1970s. It was a time of extreme recession, depression in the United States after the Vietnam War.

(2:33)

There were mass closings of research laboratories. Although the corollary of this timing was that the cycle, the life cycle, of technological improvement seems to be that every 30 or 40 years there is enough change in how technology and innovation and the courts and everything else work that it’s time for a massive study and upheaval. At that time we cast our minds back to what ended up in the 1951 Patent Act and we considered all of the changes in technology after World War II, the blossoming in chemistry and physics, the beginnings of the biotechnological what became a revolution.

And at the same time every problem, every concern that I heard mentioned half an hour ago were real and increasing. You couldn’t count on your patent rights any patent. The Supreme Court announced famously that the only valid patent is one they hadn’t got their hands on.

(3:51)

The antitrust division targeted patents because everyone knows that monopolies are evil and un-American. And there were mass closings of research laboratories. I was at that time on the board of the American Chemical Society and the whole laboratories were shutting down even though this was getting to be recognized as the heyday of chemistry and the beginning of the heyday of biotechnology and biochemistry.

And all of the concerns focused on commercial incentive, the practicalities, how can we count on our property rights for anything if it’s just a matter of time before someone finds a sympathetic forum because forum shopping among the circuits was reasonable. And all of the other issues, they weren’t focused heavily on biological areas because of the state of the science, but there was enough to be realistic. So, when President Jimmy Carter formed at the presidential level the most complex experience and he hoped wisest group of 20 or 30 leaders from the nation to figure out what to do about investment in innovation, technological innovation.

(5:33)

He called it a domestic policy review of technological innovation. 20 or 30 of us gleaned on factors that depending on what people were doing in bar associations or what they had written, representatives, the so-called public interest, then as now talking about the cost of drugs, the problems with introducing new drugs, the antitrust division, anyone you could think of because the commissioner of patents was Don Banner at the time. I was a member of this group.

And after I would say two years of vigorous debate, all of it under the so-called Chatham House rules, so there was some very plain talk as research directors from some of the largest industries in the nation or in the world gave hard facts as to projects and products that were being dropped because of uncertainties as to protection, as to commercial enterprise, as to the opportunity to pay for your failed research as well as the successful research.

(6:55)

And that ended up in a lot of areas besides patents. There were labor aspects. There were tax incentive aspects and so on.

And in the patent area, it was the groundwork for the Bayh-Dole Act, the Hatch-Waxman Act, and the Federal Circuit formed directly to confront the uncertainty, the unpredictability, and even worse than unreliability, the flaws, the errors that judges were made. Because even now as I listened to our concern, I had the same thought that I had 50 years ago. If you had an appropriately wise and experienced judge, you wouldn’t have to seek the legislative areas, not in Bayh-Dole or Hatch-Waxman, those were congressional changes that were necessary.

(7:57)

But even so, it required persuasion, Bayh-Dole, the idea that if the government pays for the research, why shouldn’t it be available to everyone rather than by exclusive license and so on, so that there was a heavy educational process taking place. But the thing, and this is really my message here, the thing that astounded me then is that you didn’t have to live with it. I had spent 30 years in industry helping, figuring out how to cope with the law and with precedent that turned up wherever it turned up.

(8:42)

The idea that that could be changed in a dramatic way in any area that was important was new to me. I hadn’t really thought that this was something that was within the province of us in the private sector. So, this is my message to you today, because it’s really the other way around.

And as I consider all of you and the interests that are represented here, to think about not just what the law is and how to cope with it, but what the law should be and how to fix it and how to change it. Because I assure you, although it’s not easy, it takes a while, but it’s there in a receptive environment to what’s best in the national interest. So that’s the message I’d like to leave with you.

Thank you for listening.

[Renee Quinn] (9:53 – 10:12)

Thank you for listening to IP Watchdog Unleashed. We will be back next week, and we hope you will join us again. In the meantime, please be sure to visit www.ipwatchdog.com to read all the latest news and information about what is happening in the intellectual property world. And also be sure to subscribe to our free daily email newsletter.